AVITA Medical, Inc. (RCEL)
16.59
+0.91
(+5.80%)
USD |
NASDAQ |
Nov 06, 16:00
16.60
+0.01
(+0.06%)
After-Hours: 20:00
AVITA Medical Research and Development Expense (Quarterly) : 4.697M for Sept. 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 4.697M |
| June 30, 2026 | 5.078M |
| March 31, 2026 | 5.629M |
| December 31, 2025 | 5.691M |
| September 30, 2025 | 3.748M |
| June 30, 2025 | 5.117M |
| March 31, 2025 | 6.284M |
| December 31, 2024 | 4.85M |
| September 30, 2024 | 5.428M |
| June 30, 2024 | 4.887M |
| March 31, 2024 | 5.194M |
| December 31, 2023 | 6.765M |
| Date | Value |
|---|---|
| September 30, 2023 | 4.394M |
| June 30, 2023 | 5.076M |
| March 31, 2023 | 4.586M |
| December 31, 2022 | 3.379M |
| September 30, 2022 | 3.799M |
| June 30, 2022 | 3.059M |
| March 31, 2022 | 3.62M |
| June 30, 2021 | 3.974M |
| March 31, 2021 | 4.109M |
| December 31, 2020 | 3.361M |
| September 30, 2020 | 3.204M |
| June 30, 2020 | 2.332M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Iovance Biotherapeutics, Inc. | 49.34M |
| Halozyme Therapeutics, Inc. | 27.78M |
| Agenus, Inc. | 11.65M |
| Amgen, Inc. | 2.111B |
| Fate Therapeutics, Inc. | 21.54M |